Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hsin-Ta Wu

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Nature Cancer|October 17, 2022
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genesJoshua J Gruber, Anosheh Afghahi, Kirsten Timms, et al.
The Oncologist|July 16, 2024
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinomaAndres F Correa, Ekaterina Kalashnikova, Hsin-Ta Wu, et al.
NPJ Precision Oncology|May 5, 2026
Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profilingCarlos Diego Holanda Lopes, Hsin-Ta Wu, Katharine Dilger, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
International Journal of Molecular Sciences|October 14, 2022
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical ResectionSara Lonardi, Halla Nimeiri, Chang Xu, et al.
Nature Genetics|December 16, 2014
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexesMark D M Leiserson, Fabio Vandin, Hsin-Ta Wu, et al.
Frontiers in Oncology|August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assayThomas Powles, Amanda Young, Halla Nimeiri, et al.
Gynecologic Oncology|September 18, 2022
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancerJune Y Hou, Jocelyn S Chapman, Ekaterina Kalashnikova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2019
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder CarcinomaEmil Christensen, Karin Birkenkamp-Demtröder, Himanshu Sethi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceRaoul Charles Coombes, Karen Page, Raheleh Salari, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Nature Cancer|October 17, 2022
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genesJoshua J Gruber, Anosheh Afghahi, Kirsten Timms, et al.
The Oncologist|July 16, 2024
Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinomaAndres F Correa, Ekaterina Kalashnikova, Hsin-Ta Wu, et al.
NPJ Precision Oncology|May 5, 2026
Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profilingCarlos Diego Holanda Lopes, Hsin-Ta Wu, Katharine Dilger, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
International Journal of Molecular Sciences|October 14, 2022
Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical ResectionSara Lonardi, Halla Nimeiri, Chang Xu, et al.
Nature Genetics|December 16, 2014
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexesMark D M Leiserson, Fabio Vandin, Hsin-Ta Wu, et al.
Frontiers in Oncology|August 21, 2023
Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assayThomas Powles, Amanda Young, Halla Nimeiri, et al.
Gynecologic Oncology|September 18, 2022
Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancerJune Y Hou, Jocelyn S Chapman, Ekaterina Kalashnikova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2019
Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder CarcinomaEmil Christensen, Karin Birkenkamp-Demtröder, Himanshu Sethi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2019
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic RecurrenceRaoul Charles Coombes, Karen Page, Raheleh Salari, et al.
Pageof 3